Concentrix (NASDAQ:CNXC) Given New $55.00 Price Target at Canaccord Genuity Group

Concentrix (NASDAQ:CNXC) had its target price decreased by stock analysts at Canaccord Genuity Group from $80.00 to $55.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price points to a potential upside of 103.33% from the company’s previous close.

CNXC has been the topic of a number of other research reports. Robert W. Baird cut their target price on shares of Concentrix from $52.00 to $40.00 and set an “outperform” rating on the stock in a research report on Wednesday. Wall Street Zen upgraded Concentrix from a “hold” rating to a “buy” rating in a research note on Saturday, February 14th. Weiss Ratings downgraded Concentrix from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday, January 29th. Finally, Barrington Research restated an “outperform” rating and set a $62.00 price objective on shares of Concentrix in a research report on Tuesday, March 17th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $54.50.

Concentrix Price Performance

NASDAQ:CNXC traded up $0.57 during trading hours on Wednesday, hitting $27.05. The company’s stock had a trading volume of 217,381 shares, compared to its average volume of 1,438,320. Concentrix has a twelve month low of $24.27 and a twelve month high of $66.00. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.40 and a quick ratio of 1.40. The stock has a fifty day simple moving average of $35.34 and a 200-day simple moving average of $40.33. The company has a market capitalization of $1.66 billion, a P/E ratio of -1.30, a PEG ratio of 0.35 and a beta of 0.50.

Concentrix (NASDAQ:CNXC) last posted its earnings results on Tuesday, March 24th. The company reported $2.61 EPS for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.03). The company had revenue of $2.50 billion during the quarter, compared to the consensus estimate of $2.49 billion. Concentrix had a positive return on equity of 16.91% and a negative net margin of 13.02%.The firm’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company posted $2.79 EPS. On average, analysts anticipate that Concentrix will post 10.11 EPS for the current fiscal year.

Insider Transactions at Concentrix

In other news, CEO Christopher A. Caldwell purchased 1,000 shares of the stock in a transaction on Thursday, January 29th. The stock was purchased at an average price of $37.07 per share, for a total transaction of $37,070.00. Following the acquisition, the chief executive officer owned 362,075 shares in the company, valued at $13,422,120.25. This trade represents a 0.28% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Concentrix

Large investors have recently modified their holdings of the company. Royal Bank of Canada lifted its holdings in Concentrix by 9.5% in the first quarter. Royal Bank of Canada now owns 47,501 shares of the company’s stock valued at $2,643,000 after buying an additional 4,133 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Concentrix by 75.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 423,287 shares of the company’s stock worth $23,552,000 after acquiring an additional 181,546 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Concentrix by 17.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 146,515 shares of the company’s stock valued at $8,152,000 after purchasing an additional 21,746 shares during the period. Focus Partners Wealth bought a new stake in shares of Concentrix during the 1st quarter valued at about $781,000. Finally, Geneos Wealth Management Inc. grew its stake in Concentrix by 532.7% during the first quarter. Geneos Wealth Management Inc. now owns 620 shares of the company’s stock worth $34,000 after purchasing an additional 522 shares during the period. 90.34% of the stock is currently owned by institutional investors and hedge funds.

Concentrix News Summary

Here are the key news stories impacting Concentrix this week:

• Positive Sentiment: Board declared a $0.36 quarterly dividend (payable May 5; ex‑dividend Apr 24), implying a ~5.4% yield and signaling shareholder return commitment — supportive for income investors. Concentrix Reports First Quarter 2026 Results
• Positive Sentiment: Company maintained full‑year guidance and reiterated growth drivers: 5.4% reported revenue growth, continued momentum in AI-enabled iX Suite enterprise wins and strength in banking vertical — this stability reduces near‑term forecast risk. Concentrix Reports First Quarter 2026 Results
• Positive Sentiment: Share repurchases continued: ~1M shares bought in Q1 at ~$40.06 with ~$396.6M remaining authorization — buybacks can support the share price over time. Concentrix Reports First Quarter 2026 Results
• Positive Sentiment: Liquidity improved via an amendment/expansion to the accounts receivable securitization facility — reduces short‑term funding risk and supports working capital. Concentrix Expands and Extends Accounts Receivable Securitization Facility
• Neutral Sentiment: Robert W. Baird trimmed its price target from $52 to $40 but kept an Outperform rating — a mixed signal (lowered upside but continued positive view). Baird Price Target Note
• Neutral Sentiment: Media and analyst coverage (Bloomberg stock movers, earnings call transcript) highlighted the print and strategic commentary—keeps the story visible to traders. Stock Movers: Concentrix, Jefferies, ImmunityBio
• Neutral Sentiment: Multiple short‑interest reports in the feed show anomalous zeros/NaN values — likely data noise rather than a genuine short squeeze/cover signal; treat as unreliable.
• Negative Sentiment: Q1 GAAP results showed sharp profit deterioration: net income fell ~69%, operating margin compressed and diluted GAAP EPS plunged; non‑GAAP EPS was slightly below last year and missed consensus by $0.03 — the profit and cash‑flow weakness is the principal negative catalyst. Concentrix Lags Q1 Earnings Estimates
• Negative Sentiment: Operating cash flow and adjusted free cash flow were negative in the quarter (cash used in operations, adjusted FCF a use), which raises short‑term liquidity and valuation concerns despite the securitization tweak. Concentrix Reports First Quarter 2026 Results
• Negative Sentiment: Market headlines noted the stock dropped after the print (headline coverage of a ~12% intraday fall), reflecting investor discomfort with the earnings quality and margin/cash metrics. CNXC Stock Drops After Q1

Concentrix Company Profile

Concentrix Inc (NASDAQ: CNXC) is a global business services company specializing in customer engagement solutions and technology‐driven business process outsourcing. The firm’s offerings encompass customer care delivered across voice and digital channels, back‐office processing, analytics and consulting, and automated workflow management. By integrating proprietary platforms, strategic partnerships and advanced automation, Concentrix helps clients enhance customer experiences and streamline operations.

Its capabilities extend to digital marketing and technology implementation, leveraging artificial intelligence, machine learning and data analytics to optimize customer journeys.